Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

Jonathan L. Kaufman, MD, Jatin J. Shah, M.D., Jacob P. Laubach, MD, Alaina R. Mitchell, BS, Cathy Sharp, R.N., Colleen Lewis, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Daniela Casbourne, FNP-BC, AOCNP, Ajay K. Nooka, MD, MPH, FACP, Leonard T Heffner, MD, Paul G. Richardson, MD, Robert Z. Orlowski, M.D., Ph.D., Sagar Lonial, MD

Blood (2012) 120 (21): 336.

https://doi.org/10.1182/blood.V120.21.336.336

Published: 2012

Journal Articles

Management of Back Pain in Myeloma Patients Using Vertebral Augmentation: A Practical Approach to Elimination of Pain and Improvement of Functional Status

Douglas B Yim, MD, Ajay K. Nooka, MD, MPH, FACP, James M Martin, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 4713.

https://doi.org/10.1182/blood.V120.21.4713.4713

Published: 2012

Journal Articles

Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry

Eden Hailemichael, Highschool student, Jonathan L. Kaufman, MD, Christopher R. Flowers, MD, Edmund K. Waller, MD, PhD, Mary Jo Lechowicz, MD, Amelia Langston, MD, Michael Graiser, PhD, Lawrence H. Boise, PhD, Sagar Lonial, MD, Ajay K. Nooka, MD, MPH, FACP

Blood (2012) 120 (21): 2072.

https://doi.org/10.1182/blood.V120.21.2072.2072

Published: 2012

Journal Articles

Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma

Loretta Nastoupil, MD, Pareen J Shenoy, MBBS, MPH, Alex Ambinder, Miray Seward, Ajay K. Nooka, MD, MPH, FACP, Edmund K. Waller, MD, PhD, Amelia Langston, MD, Jonathan L. Kaufman, MD, Nassoma King, PA, Mary Jo Lechowicz, MD, Sagar Lonial, MD, Rajni Sinha, MD, MRCP, Christopher R. Flowers, MD

Blood (2012) 120 (21): 2006.

https://doi.org/10.1182/blood.V120.21.2006.2006

Published: 2012

Journal Articles

Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins

Shannon M. Matulis, Ph.D., Jiangxia Liu, Ph.D., Vikas A. Gupta, MD, PhD, Jason E. Conage-Pough, Ajay K. Nooka, MD, MPH, FACP, Edmund K. Waller, MD, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD

Blood (2012) 120 (21): 4024.

https://doi.org/10.1182/blood.V120.21.4024.4024

Published: 2012

Journal Articles

Impact of Body Mass Index (BMI) On Overall Survival in Myeloma

Mukesh Kumar, MD, Ajay K. Nooka, MD, MPH, FACP, Amelia Langston, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Melanie Watson, Hannah Collins, ANP-BC, OCN, Daniela Casbourne, FNP-BC, AOCNP, Lawrence H. Boise, PhD, Jonathan L. Kaufman, MD, Edmund K. Waller, MD, PhD, Sagar Lonial, MD

Blood (2012) 120 (21): 4289.

https://doi.org/10.1182/blood.V120.21.4289.4289

Published: 2012

Journal Articles

Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis

Ajay K. Nooka, MD, MPH, FACP, Madhusmita Behera, Lawrence H. Boise, PhD, Melanie Watson, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1855.

https://doi.org/10.1182/blood.V118.21.1855.1855

Published: 2011

Journal Articles

Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Nutan J. DeJoubner, MD, Ajay K. Nooka, MD, MPH, FACP, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Ryan M Ziemiecki, MS, Jamie H. Hirata, PharmD, Brian K Link, MD, Christopher R Flowers, MD

Blood (2011) 118 (21): 775.

https://doi.org/10.1182/blood.V118.21.775.775

Published: 2011

Journal Articles

A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials,

Ajay K. Nooka, MD, MPH, FACP, Samatha Muppidi, MD, R. Donald Harvey, PharmD, Jonathan L. Kaufman, MD, Amelia Langston, MD, Colleen Lewis, MSN, Lawrence H. Boise, PhD, Christopher R Flowers, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 3954.

https://doi.org/10.1182/blood.V118.21.3954.3954

Published: 2011

Journal Articles

Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis

J. Mark Prichard, MD, Samatha Muppidi, MD, Christopher R Flowers, MD, Jonathan L. Kaufman, MD, Mary Jo Lechowicz, MD, Sagar Lonial, MD, Ajay K. Nooka, MD, MPH, FACP, Rajni Sinha, MD, MRCP, Edmund K Waller, MD, PhD, Amelia Langston, MD

Blood (2011) 118 (21): 1959.

https://doi.org/10.1182/blood.V118.21.1959.1959

Published: 2011

Journal Articles

The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),

Ajay K. Nooka, MD, MPH, FACP, Jonathan L. Kaufman, MD, Madhusmita Behera, Charise Gleason, Amelia Langston, MD, Conor Ermst Steuer, MD, Christopher R Flowers, MD, Lawrence H. Boise, PhD, Sagar Lonial, MD

Blood (2011) 118 (21): 3994.

https://doi.org/10.1182/blood.V118.21.3994.3994

Published: 2011

NARROW

Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

Management of Back Pain in Myeloma Patients Using Vertebral Augmentation: A Practical Approach to Elimination of Pain and Improvement of Functional Status

Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry

Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma

Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins

Impact of Body Mass Index (BMI) On Overall Survival in Myeloma

Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis

Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials,

Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis

The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only